Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 27,
2018
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36498
|
|
86-1032927
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408)
973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of
the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.07 Submission of Matters to a Vote of
Security Holders.
On
April 27, 2018, Cellular Biomedicine Group, Inc. (the
“Company”) completed its 2018 annual meeting of
stockholders (the “Annual Meeting”). The number of
shares of common stock entitled to vote at the Annual Meeting was
17,003,968 shares. The number of shares of common stock present or
represented by valid proxy at the Annual Meeting was 13,771,658
shares. All matters submitted to a vote of the Company’s
stockholders at the Annual Meeting were approved, and Wen Tao
(Steve) Liu, Nadir Patel and Bosun S. Hau were elected “Class
III” directors.
The
following is a tabulation of the voting on the proposals presented
at the Annual Meeting:
(i) To
elect three (3) “Class III” directors, each of whom
will be elected for a term of three years, or until the election
and qualification of their successors.
|
Nominee
|
|
Shares Voted
For
|
|
Shares
Withheld
|
|
Broker
Non-Vote
|
|
Wen Tao
(Steve) Liu
|
|
10,467,304
|
|
99,156
|
|
0
|
|
Nadir
Patel
|
|
10,451,941
|
|
114,519
|
|
0
|
|
Bosun
S. Hau
|
|
10,343,972
|
|
222,488
|
|
0
|
(ii) To
ratify the appointment of BDO China Shu Lun Pan Certified Public
Accountants LLP as the Company’s independent registered
public accounting firm for the fiscal year ending December 31,
2018.
|
Shares Voted
For
|
|
Shares Voted
Against
|
|
Shares
Abstaining
|
|
Broker
Non-Vote
|
|
13,747,957
|
|
20,173
|
|
3,528
|
|
3,205,198
|
Item 7.01 Regulation FD
Disclosure.
On
April 30, 2018, the Company issued a press release announcing the
results of the Annual Meeting. A copy of the press release is
attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
99.1
Press Release, dated April 30, 2018
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
|
|
Date:
April 30, 2018
|
By:
|
/s/
Bizuo (Tony) Liu
|
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|